焦　

點　

人　

物

台大藥刊

�

主任的話

‧李水盛主任

今年上半年對本系而言大有「多事」之秋之慨。從1月14日之陳春雄老師榮退，繼

以3月25日舉辦孫教授之追思紀念會，4月18日許照惠系友會見李校長而簽署建藥學館

承諾書事件，而隨之而來之藥學系改制計畫-擬四年制、六年制雙軌並行，藥學館籌建

規劃，與新成立之分子醫藥學程師資之遴聘，其間穿插著2月1日第41屆系友郭錦樺及

8月1日本系第一位博士班畢業生沈雅敬老師之到聘、高純琇老師借調財團法人醫藥品

查驗中心、第10屆系友之畢業四十週年與第20屆系友畢業三十週年返校活動（4月29

日），林林總總，不一而足。

這些事情，有些代表著系的薪火相傳已階段性完成，即第一代之師資已由第二

代以後之專才接棒。值得一書的事，林慧玲老師自8月1日起擔任藥劑部主任，開啟由

臨床藥學專業師資擔任斯職之首例，爾後想必有一番新氣象。

自許系友承諾捐款蓋藥學大樓之後，9月9日在其積極運籌下成立臺大藥物科技

發展基金會之雛型，預計在年底前能正式運作，以彙集並整合系友之力量，全力促成

臺大藥學之夢—具充分發展空間之世界一流藥學院。此臺大藥學永續經營規劃及系友

之熱心參與，已被校長譽為臺大前所未有之典範。期盼在眾志成河之前提下，群策群

力，早日圓夢。

49期���

焦　

點　

人　

物

�

2006年傑出系友得獎人－方森茂校友

‧Sen-Maw Fang, Ph.D.

Dr.Sen-MawFanggraduatedfromtheSchoolofPharmacy,National

TaiwanUniversityin1959（第三屆）andwentontoreceiveM.S.andPh.D.

degreesfromtheCollegeofPharmacy,UniversityofIllinoisin1968.Hethen

post-doctoredattheBenMayCancerResearchInstitute,UniversityofChicago

andworkedonareasofandrogenreceptorsinratprostate.Theworkculminated

intheidentificationoftestosteroneconversiontodihydrotestosterone(DHT)

inthenucleiofprostaticcellsby5-alphareductase.DHTwasfoundtobethe

activeandrogeninprostateandwasimplicatedinprostatichypertrophyand

prostatecancer.

In1971,he accepted a teaching job at both theDepartmentofPharmacyand theDepartmentof

Pharmacologyat theCollegeofPharmacy,UniversityofUtah. Hecontinuedtoworkonandrogenreceptors

inhumanprostatethroughfundingbyNationalCancerInstitute.HealsoreceivedNICHDfundingtoworkon

thepharmacokineticsofestrogenandprogestinsintheuterinehornofratsafterIUDadministration.Through

agroupproject,healsostudiedthepharmacokineticsofnorethindronereleasefromapolyglutamatepolymer

deviceafter i.m. injection. Healsoreceivedgrants toworkon thebioavailabilityandpharmacokineticsof

minerals inrat intestinesbeforeandafter themineralswerechelatedwithvariousligands Healsoservedas

consultantinchelatedmineralsforinternalaswellascosmeticapplications.DuringhistenureintheUniversity

ofUtah,hetaughtbothundergraduateandgraduatecoursesinbiopharmaceuticsandpharmacokineticsinthe

CollegeofPharmacyandalsoparticipatedingrouplecturestoMasterdegreestudentsintheCollegeofNursing

andtheCollegeofMedicine.

Dr.Fangleft theacademyin1985topursuefull timehisentrepreneurship. HeestablishedAMTLabs

inSaltLakeCity,whichisarawmaterialsupplier tomostlynutritionalfoodsupplementindustries. Besides

chemicalsynthesisofchelatedminerals, thecompanyalsomakeotheringredientswhichtotalmorethan300

items.AMTalsoprovidespecialformulationssuchassustainedreleasetablets,directlycompressablegranules,

effervescentpowders,energydrinks,highsolubilitymineralproduct,etc.Thecompanyhasproductsmarketed

allovertheworld.

He isnowsemi-retiredandspendhis timemostlyonerhu (ChineseTraditionalOrchestra), singing

(baritonesoloistinthechorus)andtennis.Hehasestablishedafoundationtohelpvariouscharityactivitiesin

SaltLakeCityandotherareas.Hismostpleasurenowistohorsearoundwithhisthreeyounggrandkids.

焦　

點　

人　

物

台大藥刊

�

Dr.JinnWuobtainedhisB.S.inPharmacyandaM.S.inPharmaceutical

ChemistryfromtheSchoolofPharmacy,NationalTaiwanUniversityin1971

（第15屆）and1975 (under the supervisionofProfessorChung-Hsiung

Chen),respectively.HeearnedaPh.D.degreeinNaturalProductsChemistry

andMedicinalChemistryfromtheCollegeofPharmacy(underthesupervision

ofProfessorsJackL.BealandRaymondDoskotch),TheOhioStateUniversity

in1979.Hewasapostdoctoralresea　rchassociateintheareasofBiomedical

MassSpectrometryanddrugmetabolismattheDepartmentofPharmacology,

CollegeofMedicine,TheOhioStateUniversity from1979 -1980. Dr.

Wu joinedFMCCorporation inPrinceton,NewJersey in1980andmade

numerouscontributionsinnewproductresearchanddevelopmentinmetabolism,bioanalyticalchemistry,and

environmentalchemistry.

Dr.JinnWuestablishedXenoBioticLaboratories,Inc.(XBL)in1987inPlainsboro,NewJersey. This

companyisconsideredasoneofthetopGLPcontractresearchlaboratoriesintheUSAwithhighreputationin

invitro/invivodrugmetabolism,pharmacokinetics,metaboliteprofiling,metaboliteidentificationandclinical

bioanalysis.

Dr.WuisamemberoftheAmericanChemicalSociety(ACS),theAmericanSocietyofPharmacognosy

(ASP), the InternationalSociety for theStudyofXenobiotics (ISSX),AmericanChinesePharmaceutical

Association (ACPA),Sino-AmericanPharmaceuticalAssociation (SAPA) and amemberofAmerican

AssociationofPharmaceuticalScientists(AAPS).Hehaspublished48scientificpapers.

Dr.Wuhasbeenveryactiveinpublicservices.HewastheTeamManagerforNTUCollegeofMedicine

SoccerTeam(1968-71)andwonNationalCollegesofMedicineChampionshipin1970. Hehasservedasa

consultantforNIH-NCIfornationalresearchgrantproposalreview,wasamemberoftheBoardofDirectorsat

ArdentPharmaceuticals,Inc.,ViceChairmanandamemberoftheBoardofDirectorsforMonteJadeScience&

TechnologyAssociation(EastCoast),PresidentofACPAandNationalTaiwanUniversitySchoolofPharmacy

AlumniAssociation–NorthAmerica(NTUSPAA-NA)2001-2003.HewastherecipientofTheJackL.Beal

PostbaccalaureateAward,CollegeofPharmacy,TheOhioStateUniversity,in1994.

2006年傑出系友得獎人－吳　晉校友

‧Jinn Wu (吳晉), Ph.D.

49期���

焦　

點　

人　

物

�

Dr.Mei-LingChen isAssociateDirector,OfficeofPharmaceutical

Science,Center forDrugEvaluation andResearch (CDER),U.S.Food

andDrugAdministration (FDA). The superofficeprovidesoversightof

scientificreviews,regulatorypoliciesandresearchactivitiesfortheOfficeof

BiotechnologyProducts,OfficeofGenericDrugs,OfficeofNewDrugQuality

Assessment,andOfficeofTestingandResearch. Over theyears,Dr.Chen

hasservedasanadvisertotheBureauofPharmaceuticalAffairs,Department

ofHealth,ExecutiveYuan,Taiwan,RepublicofChina. Since2001,shehas

beenrecognizedasaFellowoftheAmericanAssociationofPharmaceutical

Scientists (AAPS),aprofessionalscientificsocietyofmore than12,000membersfromacademia, industry,

governmentandotherresearchinstitutesworldwide.SheisontheEditorialBoardofClinicalPharmacokinetics,

aco-editorof thebookentitled“ClinicalTrialsofDrugsandBiopharmaceuticals＂,a refereeofseveral

prestigiousscientificjournals,andtheauthororco-authorofnumerousreviewarticles,bookchapters,research

papersandabstractsinthefieldofclinicalpharmacologyandbiopharmaceutics.

Dr.Chenwasborn inTaiwanandreceivedherB.S. inPharmacyfromtheNationalTaiwanUniversity

（第18屆）. SheearnedherPh.D.inPharmacokineticsandBiopharmaceuticsfromtheUniversityofIllinois

atChicagoin1982. Followingatwo-yearpostdoctoral training,Dr.ChenjoinedtheFDAin1984. Shewas

honoredasaregulatoryexpert in1990andadvancedtoChief,PharmacokineticsEvaluationBranch,Division

ofBiopharmaceutics,OfficeofResearchResourcesin1994. Dr.ChenwaspromotedtoDirector,Divisionof

PharmaceuticalEvaluationII,OfficeofClinicalPharmacologyandBiopharmaceuticsin1995,andAssociate

Director,OfficeofPharmaceuticalSciencein2000.

WhileintheFDA,Dr.ChenhasbeenappointedasCo-ChairoftheComplexDrugSubstancesCoordinating

Committee,andTopicLeadoftheBiopharmaceuticsCoordinatingCommitteeinCDER.Shehasalsoserved

aschairpersonorco-chairpersonofseveralworkinggroupsonhighlycontroversialand/orimportantscientific

issues.SheisinstrumentalinthedevelopmentofmanyFDAguidanceandpolicydocumentsforpharmaceutical

industryandFDAstaff,inparticular,onthetopicsrelatedtobioavailabilityandbioequivalence.Dr.Chenhas

receivednumerousmeritawardsfromtheFDA.

Asascientificandregulatoryexpert,Dr.Chenhasfrequentlybeenrequestedasaspeakerormoderator

atnationalandinternationalmeetings.From2000to2005,shewaselectedtoserveontheU.S.Pharmacopeia

(USP)ExpertCommittee-BioavailabilityandNutrientAbsorption. Additionally,shewasontheUSPExpert

Panel-ActiveComplexesfrom2003to2004andontheUSPAdvisoryPaneltotheInternationalHealthExpert

Committeein2005.

2006年傑出系友得獎人－陳美玲校友

‧Mei-Ling Chen, Ph.D.

焦　

點　

人　

物

台大藥刊

�

2006年傑出系友得獎人－黃秀美校友

‧Amy Huang

AmyHuangisVicePresidentandAreaDirectorofGlaxoSmithKline.She

isresponsibleforallcommercialoperationsofGlaxoSmithKlineinChinaand

HongKong.

MsHuangwasborninTaiwanandearnedherB.S.inPharmacyatNational

Taiwan University（第19屆）. From 1997 to 2005, Ms. Huang was the

ManagingDirectorforGlaxoSmithKlineTaiwan.Thisfollowedhertenureasthe

MarketingDirectorforSmithKlineBeechamfrom1993to1997.

Between1982to1993,Ms.HuangheldvariouspositionswithinSmithKline

BeechamPharmaceuticals, includingActingSalesManager,ProductManager,

MedicalandClinicalResearchManager,MarketingManager,andBusinessDevelopmentDirector (Taiwan

&China).Prior to this,Ms.Huangplayedvariousroles fromsales training,product regulatory toproduct

managementforalocalpharmaceuticalcompany,Su-Chiang&Co.Ltd.(ThesoleagentforSK&F)from1976

to1982,aftergraduatingwithadegreeinPharmacyfromtheNationalTaiwanUniversity.

Ms.Huang isanactivememberofmany industryassociations.Shemost recentlyservedasCo-Chair

for thePharmaceuticalCommitteeofEuropeanChamberofCommerceTaipei (ECCT),andChaired the

CommunicationsCommitteeofTaiwan´s InternationalResearch-BasedPharmaceuticalManufacturers

Association(IRPMA).ShewasaBoardmemberof theTaiwanPharmaceuticalMarketing&Management

Association(TPMMA),andaDirector for the IRPMAand theTaiwanProductQualityResearchInstitute

(TPQRI).ShewasamemberofboththeAmericanChamberofCommerceinTaiwanandtheBritishChamberof

CommerceinTaipei.NowsheisoneoftheECRDPACinChina.

Ms.Huangisaninspirational leaderandsuccessfulexecutive. Hernumerousawardsandachievements

includeOutstandingPharmaceuticalManager(Taiwan)andGSK´sInspirationalLeadershipAward(2005).

Since themergerofGlaxoWellcomeandSmithKlineBeechamin2001,shepresidedover recordcountry

performanceduringa turbulentperiodofregulation.Duringher tenureasManagingDirectorofSmithKline

BeechamTaiwan,sheoversawthelaunchesofEngerixB,Tagmet,Augmentin,AvandiaandSeretideetc., the

mostsuccessfulblockbustersinTaiwanPharmaceuticalindustryhistory.

GSKisaworldleadingresearch-basedpharmaceuticalcompanywithapowerfulcombinationofskillsand

resourcesthathelppeoplearoundtheworlddomore,feelbetterandlivelonger.